Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

IGF-1 LR3 peptide icon, one bubble per amino acidIGF-1 LR383 residuesMFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

IGF-1 LR3

Beginner tier: 20 mcg, daily · community consensus

Anti-AgingResearch
~20-30 hours half-life·Injection

Also known as: Long R3 IGF-1, LR3 IGF-1, IGF-1 Long R3

Regular IGF-1 stays active for about 15 minutes. The LR3 modification stretches that to 20 to 30 hours. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant 83-amino acid protein that sidesteps IGF binding proteins almost entirely, leaving most of the circulating compound free and active. That extra exposure time is exactly what makes it both powerful and risky. No human clinical trial has tested LR3 for anabolic endpoints; animal models from Conlon et al. [1] confirmed organ growth at sustained high doses. Community evidence across hundreds of threads on r/Peptides and r/steroids points to meaningful lean mass gains within 4 to 6 week cycles at 20 to 50 mcg per day.

What Is IGF-1 LR3?

Fifteen minutes. That is how long native IGF-1 stays unbound and active in circulation before binding proteins snatch it up. The LR3 variant rewrites that timeline completely.

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1, also called Long R3 IGF-1) is an 83-amino acid recombinant protein with a 13-amino acid N-terminal extension plus an arginine-to-glutamate substitution at position 3. These changes reduce binding protein affinity by over 100-fold (Ballard et al.)[2]. The result is a compound that circulates mostly free with a functional half-life of 20 to 30 hours.

IGF-1 sits downstream of growth hormone in the anabolic signaling cascade. GH tells the liver to produce IGF-1; IGF-1 then activates the IGF-1 receptor, triggering the PI3K/Akt/mTOR pathway that drives protein synthesis, satellite cell activation, and muscle cell hyperplasia. LR3 hits those same receptors with 2 to 3 times the potency of native IGF-1 and holds onto them far longer.

In practice, most users run 20 to 40 mcg per day subcutaneously for 4 to 6 weeks, followed by 4 to 6 weeks off to restore receptor sensitivity. Community reports across hundreds of r/Peptides and r/steroids threads consistently describe improved recovery, muscle fullness, and lean mass accrual within the first 3 to 4 weeks. The trade-off is real. Hypoglycemia hits if peri-injection nutrition is missed. Conlon et al. [1] documented organ enlargement in guinea pigs at 120 mcg per day continuous infusion. A Lancet meta-regression [3] linked raised circulating IGF-1 to increased cancer risk. No human RCT has validated the dosing protocols in community use.

How IGF-1 LR3 Works

IGF-1 LR3 binds the same type 1 IGF receptor (IGF-1R) as native IGF-1, but it does so with a critical pharmacokinetic advantage. Native IGF-1 is 98% sequestered by six known IGF binding proteins (IGFBPs 1 through 6), which limit free-fraction exposure to roughly 12 to 15 minutes. The LR3 modification drops IGFBP affinity by over 100-fold (Ballard et al.)[2], so most of the injected compound circulates unbound.

Once LR3 occupies IGF-1R, it triggers the same intracellular cascade as native IGF-1. Receptor autophosphorylation activates insulin receptor substrate proteins, which recruit PI3K. PI3K generates PIP3, activating Akt. Akt then phosphorylates mTOR, the master regulator of protein synthesis and cell growth. This pathway drives two anabolic processes: hypertrophy (larger muscle fibers through increased protein synthesis) and hyperplasia (new muscle cell formation through satellite cell activation).

IGF-1R also mediates GLUT4 translocation to the cell membrane, explaining the hypoglycemia risk. The receptor sits on skeletal muscle and on nearly every other tissue type. Sustained occupancy from a 20 to 30 hour half-life compound means the colon, kidneys, adrenals, and spleen all receive growth signaling alongside muscle. Conlon et al. [1] confirmed this in guinea pigs; a 7-day continuous infusion raised the relative weight of the adrenals, gut, kidneys, and spleen.

Receptor downregulation begins after 4 to 6 weeks of daily administration as cells reduce surface IGF-1R density in response to chronic saturation.

IGF-1 LR3 Benefits

  • IGF-1 LR3 benefits center on sustained IGF-1 receptor activation that outlasts every other IGF-1 variant by hours.
  • Muscle cell hyperplasia, the creation of entirely new muscle fibers through satellite cell activation, is the effect that separates IGF-1R agonists from standard anabolics. Most compounds only drive hypertrophy.
  • Recovery between training sessions improves within the first 2 weeks according to hundreds of community reports on r/Peptides. Reduced DOMS and faster between-session repair are the most consistently cited user outcomes.
  • A single daily injection covers the full 24-hour window. DES clears in 25 minutes and requires multiple daily pins; LR3 sits in circulation for 20 to 30 hours.
  • Lean mass accrual in caloric surplus becomes visible by weeks 3 to 4 in most user reports. Fat reduction sometimes accompanies lean tissue gains toward the end of cycle.
  • Stacking with exogenous GH (2 to 4 IU per day) allows lower GH doses for an equivalent anabolic effect, reducing GH-related water retention and cost.

IGF-1 LR3: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 7 key studies·Research only

Long-acting IGF-1 analog with confirmed anabolic and organ-growth effects in animal models.

Dosing studied: 20-50 mcg/day (extrapolated from animal safety margins; no human dose-finding trial)
Read the evidence (key study, limitations)

Cancer proliferation signal reinforced by 2024-2025 literature. No human RCT for anabolic use. Mechanism well-established; clinical dosing entirely extrapolated.

Key Study

Conlon et al. 1995 (PMID 7561636): guinea pig organ growth at 120 mcg/day continuous infusion; Ballard et al. 1996 (PMID 8708565): SC potency preserved with minimal IGFBP binding

Limitations

No human RCT for muscle hypertrophy or anabolic endpoints. All organ-growth and potency data from animal models (guinea pig, rat). Cancer risk data (PMID 15110491) is epidemiological IGF-1 association, not LR3-specific. Formal human PK study does not exist.

Community Experience
Strong
3.5/5
Based on hundreds of threads in r/Peptides and r/steroids

Consistently reported lean mass accrual and improved recovery in 4-6 week cycles.

Community dosing: 20-50 mcg/day; beginner 20 mcg/day, intermediate 40-50 mcg/day; 80 mcg cited upper bound with diminishing returns and escalating risk
Read the reports (what users report 4, common issues 5)

Hypoglycemia and organ growth concerns lower enthusiasm vs. raw anabolic potential. Most respected experienced users treat 20-40 mcg/day as the practical ceiling.

What users report (4)
  • Meaningful lean mass accrual (especially in caloric surplus) within 4-6 weeks
  • Single daily injection due to 20-30h half-life: dosing flexibility vs. DES
  • Enhanced recovery: reduced DOMS, faster between-session repair
  • Works with exogenous GH: allows lower GH doses for equivalent anabolic effect
Common issues (5)
  • Hypoglycemia risk: requires strict peri-injection nutrition management
  • Organ growth concern at 60-80 mcg/day deters sustained high-dose use
  • Product quality highly variable: grey-market LR3 frequently underdosed or contaminated
  • Receptor desensitization if cycles exceed 6 weeks
  • Expensive per-cycle cost vs. secretagogues
Partially Aligned

Mechanism and approximate dosing are consistent between science and community. Science focuses on organ growth risk, cancer signal, and lack of human data: risks community underweights. Community reports confirm anabolic effects predicted by receptor biology but no human trial validates the specific dosing protocols in use.

IGF-1 LR3 Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner20 mcg
DailyTrack
Moderate40 mcg
DailyTrack
Aggressive80 mcg
DailyTrack
Note:

Reconstitution math for a 1mg vial: add 1.0 mL bacteriostatic water. That gives you 1,000 mcg per mL. On a U-100 insulin syringe, each unit (tick mark) equals 10 mcg. So 2 IU = 20 mcg (beginner dose), 4 IU = 40 mcg (moderate), 8 IU = 80 mcg (aggressive).

One vial at 40 mcg per day lasts 25 days, enough for a full 4-week cycle with one day to spare. At the beginner dose, a single vial covers 50 days.

Store reconstituted vials refrigerated at 2 to 8 degrees C. Discard after 28 to 30 days. Never freeze reconstituted solution.

The thing most beginners miss: eat within 15 to 30 minutes of injecting. Post-workout timing is popular because you'll be eating anyway. Morning fasted works too, just have food ready before you pin.

Get baseline bloodwork (serum IGF-1, fasting glucose, HbA1c) before your first cycle. If your natural IGF-1 is already high-normal or above, adding LR3 on top increases proliferation risk.

Calculate your IGF-1 LR3 dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

IGF-1 LR3 Protocols by Goal

beginnerCommunity4 weeks on, 4-6 weeks off
Intro & Acclimation
Wk 1-2
20 mcg · Daily · Subcutaneous
Maintenance
Wk 3-4
20 mcg · Daily · Subcutaneous

Expected: Moderate lean mass support; improved recovery; minimal organ growth risk at 20 mcg/day

Monitor: Baseline serum IGF-1 and fasting glucose before starting. Check fasting glucose weekly during cycle.

How to Use IGF-1 LR3

  1. 1
    Step 1

    Gather supplies: 1mg IGF-1 LR3 lyophilized vial, 1.0 mL bacteriostatic water, U-100 insulin syringe (29 to 31 gauge), alcohol swabs.

  2. 2
    Clean both vial stoppers with alcohol swabs

    Draw 1.0 mL (100 units) of bacteriostatic water into a syringe. Inject slowly down the inside wall of the LR3 vial. Swirl gently until dissolved. Never shake.

  3. 3
    Draw your dose using a fresh insulin syringe

    For a 20 mcg dose, draw to the 2 IU mark. For 40 mcg, draw to the 4 IU mark. For 80 mcg, draw to the 8 IU mark.

  4. 4
    Choose your injection site

    Subcutaneous: pinch abdominal fat or upper thigh, insert needle at a 45-degree angle. Intramuscular: inject into the trained muscle for purported site-enhancement effect. Inject slowly over 5 to 10 seconds.

  5. 5
    Step 5

    Eat protein and carbohydrates within 15 to 30 minutes of injection to manage the glucose-lowering effect. Post-workout is the most common timing because nutrition follows naturally.

  6. 6
    Rotate injection sites daily to avoid lipodystrophy

    Cap and refrigerate the reconstituted vial immediately after use. Discard after 28 to 30 days.

  7. 7
    Step 7

    Monitor fasting blood glucose daily during the first week, then weekly for the remainder of the cycle. Stop the cycle and consult a physician if fasting glucose drops below 60 mg/dL.

Alternative Routes

Subcutaneous (abdominal or thigh)

No dose adjustment; systemic bioavailability equivalent to IM for a long-acting compound

Easiest injection; consistent systemic distribution; preferred for full-body anabolic effect

Intramuscular (trained muscle)

Same dose as SubQ; slightly faster initial absorption but identical half-life

Community uses IM into the trained muscle for purported localized hypertrophy at injection site; this site-enhancement effect is anecdotal and not confirmed in peer-reviewed literature; glucose risk profile is identical to SubQ

Mixing your own vial? Use the IGF-1 LR3 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

IGF-1 LR3 Stacking Protocols

Works With

Avoid

IGF-1 DES

Both activate IGF-1R: LR3 provides continuous systemic stimulation (20-30h) while DES provides a sharp local pulse (~25 min). Stacking creates additive receptor load, amplifies organ growth risk significantly, and prolongs hypoglycemia window. Treat as mutually exclusive alternatives, not complements.

Do not combine
Insulin

Compounding hypoglycemia risk is extreme. LR3 already lowers blood glucose via IGF-1R-mediated glucose uptake; adding exogenous insulin without expert-level glucose management and continuous glucose monitoring creates life-threatening hypoglycemia risk. Requires clinical expertise, not community-level self-administration.

Do not combine

How much does IGF-1 LR3 cost?

Typical price

$59.99 to $96.02 per mg

Typical $79.00

Middle half of 80 US prices for 1 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

IGF-1 LR3 Side Effects

Hypoglycemia is the most immediate safety concern with IGF-1 LR3. The compound activates GLUT4 translocation through IGF-1R, pulling glucose from the bloodstream into cells. Miss your peri-injection meal and blood sugar can drop fast. Symptoms include tremor, confusion, sweating, and dizziness. This is not a maybe-someday risk; community reports treat it as a certainty during the first week if nutrition timing is off. Keep 15 to 20 grams of fast-acting carbohydrates (glucose tablets, juice) within reach at every injection.

Organ growth is the concern that keeps experienced users conservative on dosing. IGF-1 receptors exist on virtually every tissue. LR3's extended half-life means 20 to 30 hours of continuous receptor stimulation per injection, hitting the colon, kidneys, adrenals, and spleen alongside skeletal muscle. Conlon et al. [1] documented significant organ enlargement in guinea pigs receiving 120 mcg per day by continuous infusion. At 20 to 40 mcg per day in short cycles, this risk is low. At 80 mcg per day or stacked with other growth-promoting compounds, it climbs.

Cancer proliferation is a legitimate concern backed by epidemiological data. A Lancet meta-regression of 3,609 cases [3] found raised circulating IGF-1 associated with increased risk of prostate, colorectal, and premenopausal breast cancer. This data reflects endogenous IGF-1 levels, not exogenous LR3 specifically, but the mechanism of action is the same receptor. Active malignancy or cancer history is a hard contraindication.

Water retention and joint discomfort are common during weeks 1 through 3. Sodium retention drives mild edema in the hands and face. Most users report this stabilizes or becomes manageable by mid-cycle.

Receptor desensitization occurs if cycles run beyond 6 weeks. Anabolic response fades as cells downregulate surface IGF-1R density. Increasing the dose to compensate makes the organ growth and hypoglycemia profile worse without restoring efficacy. The correct response is to stop and allow 4 to 6 weeks off for receptor recovery.

Product quality variance adds a layer of risk unique to research-grade compounds. LR3 is an 83-amino acid recombinant protein requiring bacterial expression systems to manufacture. Anti-doping labs and community testing consistently document counterfeits and underdosed vials in the grey market. A blunted response at expected doses may indicate a bad product, not a dosing problem.

When to stop: fasting glucose below 60 mg/dL, persistent joint pain, visible soft-tissue swelling, or signs of rapid visceral enlargement. When to see a doctor: any hypoglycemic episode involving confusion or loss of consciousness, unexplained abdominal distension, or new lumps or masses anywhere in the body.

Contraindications: active or prior malignancy, pregnancy or breastfeeding, type 1 or poorly controlled type 2 diabetes, individuals under 18 or with open growth plates, known hypersensitivity to IGF-1, and active acromegaly or raised baseline IGF-1.

Common Issues & Solutions

Hypoglycemia: Pre-prepare 15-20g fast carbs (glucose tablets, juice) at injection time. Do not inject fasted without immediate food. If symptomatic (tremor, confusion, sweating), consume carbs immediately and measure BG. Persistent episodes: lower dose by 50% or stop cycle.

Product authenticity: an HPLC purity COA is the only check. LR3 is an 83-AA recombinant protein: synthesis requires bacterial expression equipment; pricing under $50/mg is a quality red flag. Underdosed vials produce blunted or absent response at expected doses.

Receptor desensitization (diminished response before week 4): Indicates premature downregulation from excessive dose or continuous-use spillover from previous cycle. Stop cycle; ensure 4-6 weeks off before restart. Do not increase dose to compensate.

IM vs. SubQ selection: IM into trained muscle is used for site-enhancement effect (purported localized hypertrophy at injection site); SubQ provides equivalent systemic distribution. Half-life is identical regardless of route. IM does not meaningfully change glucose risk profile.

Off-cycle length: Minimum 4 weeks off; 4-6 weeks preferred for IGF-1R sensitivity restoration. Re-check serum IGF-1 before restarting. If IGF-1 remains elevated (>250 ng/mL) at the 4-week mark, extend off-cycle.

Ask AI about this page

Ask AI for a second opinion on IGF-1 LR3 dosing and side effects

Contraindications

  • Active or history of any malignancy (IGF-1R activation may promote tumor proliferation)
  • Pregnancy or breastfeeding
  • Type 1 or poorly controlled type 2 diabetes (high hypoglycemia risk)
  • Individuals under 18 or with open growth plates
  • Known hypersensitivity to IGF-1 or related peptides
  • Active acromegaly or elevated baseline IGF-1 levels

Drug Interactions

  • Insulin: significantly increased hypoglycemia risk; concurrent use requires careful glucose monitoring
  • Sulfonylureas and other hypoglycemic agents: additive blood sugar lowering effects
  • Growth hormone (HGH): combined IGF-1 axis stimulation; may amplify side effects including water retention and glucose dysregulation
  • GLP-1 receptor agonists (semaglutide, tirzepatide): both affect glucose homeostasis; monitor blood sugar if combining
  • Corticosteroids: may blunt IGF-1 anabolic effects through catabolic opposition
  • Both activate IGF-1R: LR3 provides continuous systemic stimulation (20-30h) while DES provides a sharp local pulse (~25 min). Stacking creates additive receptor load, amplifies organ growth risk significantly, and prolongs hypoglycemia window. Treat as mutually exclusive alternatives, not complements.

Product Quality

Recommended Monitoring

TestWhenTarget
Serum IGF-1Baseline before cycle; optional mid-cycle (week 2-3)Baseline: within lab reference range; mid-cycle: not exceeding ~300 ng/mL (upper normal)
Fasting glucoseBaseline pre-cycle; daily during first week; weekly thereafter70-100 mg/dL fasting; concern if <60 mg/dL
HbA1cBaseline pre-cycle<5.7% (normal); >6.5% = relative contraindication
Comprehensive metabolic panel (CMP)Baseline; end of cycle if >4 weeks or stacked with GHWithin normal reference ranges
Serum IGF-1

Elevated baseline IGF-1 is a contraindication; mid-cycle check confirms LR3 is exerting expected effect and serum IGF-1 is not supraphysiologically elevated

Fasting glucose

IGF-1R activation drives GLUT4-mediated glucose uptake; hypoglycemia is the most common acute adverse effect

HbA1c

Identifies pre-existing glucose regulation issues that markedly increase hypoglycemia risk

Comprehensive metabolic panel (CMP)

Kidney and liver function monitoring; prolonged IGF-1R stimulation at higher doses can drive renal enlargement

IGF-1 LR3 Before and After

Days 1-3

Initial blood glucose fluctuations may occur. Mild pump sensation in trained muscles reported anecdotally. No visible body composition changes yet.

Weeks 1-2

Increased muscle fullness and pumps during training. Water retention possible. Appetite may increase. Monitor blood sugar around dosing.

Weeks 3-4

Noticeable improvements in recovery between sessions. Early lean mass gains become apparent. Localized muscle growth at injection sites reported in IM protocols.

Weeks 5-6
end of typical cycle

Peak lean mass accrual and recovery benefits. Cycle off after 4-6 weeks to maintain IGF-1R sensitivity. Fat reduction may accompany lean tissue gains.

What to Expect

Days 1 through 3 (Acclimation): IGF-1R occupancy begins within 1 to 2 hours of the first injection. Blood glucose fluctuations are common, especially when injecting fasted. Some users notice a mild pump sensation in trained muscles. Nothing visible changes in body composition this early. Keep fast-acting carbs nearby; hypoglycemia symptoms hit hardest before your nutrition timing locks in.

Weeks 1 through 2 (Early Response): Muscle fullness and pumps during training pick up noticeably. Water retention may show in the face and hands. Appetite tends to increase as the metabolic demand rises. The PI3K/Akt/mTOR pathway is actively upregulating protein synthesis at this point. Blood glucose management gets easier as you dial in meal timing around injections.

Weeks 3 through 4 (Peak Response): This is when the cycle earns its reputation. Recovery between sessions improves enough that most users notice it without looking for it. Early lean mass gains become visible, particularly for those in caloric surplus. Users running IM protocols into trained muscles report localized growth at injection sites, though this remains anecdotal. Hypoglycemia episodes typically decrease as peri-injection nutrition becomes routine.

Weeks 5 through 6 (Late Cycle): Peak lean mass and recovery benefits. Fat reduction sometimes accompanies lean tissue gains. Response may plateau compared to weeks 3 through 4 as IGF-1R begins downregulating from continuous saturation. Most experienced users cap their cycle here. Extending beyond 6 weeks increases cumulative organ growth exposure without proportional benefit.

Off-cycle, weeks 1 through 6 post: Muscle fullness drops slightly as water retention resolves. Strength and lean mass gains are generally retained with adequate nutrition. IGF-1R density recovers over 4 to 6 weeks. Check serum IGF-1 before restarting; if levels remain above 250 ng/mL at the 4-week mark, extend the off-cycle.

Detailed Timeline: Science vs Community

Days 1-3
Science

IGF-1R occupancy begins within 1-2 hours. Glucose lowering effect (IGF-1R-mediated GLUT4 translocation) starts immediately. No tissue changes visible this early.

Community

Mild pump sensation in trained muscles. Blood glucose fluctuations common, especially if injecting fasted. No visible body composition changes.

Weeks 1-2
Science

Upregulated protein synthesis via IGF-1R → PI3K/Akt/mTOR pathway. Mild fluid retention from sodium retention. Appetite increase from metabolic demand.

Community

Increased muscle fullness and pumps during training. Water retention (faces/hands). Appetite increase. Monitor blood glucose diligently.

Weeks 3-4
Science

Sustained IGF-1R stimulation drives myosatellite cell activation and protein anabolism.

Community

Noticeable recovery improvement between sessions. Early lean mass gains visible. Localized muscle growth at IM injection sites reported anecdotally. Hypoglycemia incidents less frequent as users adapt nutrition timing.

Weeks 5-6 (extended cycle)
Science

IGF-1R downregulation begins with continuous saturation. Cumulative organ growth exposure increases. No additional tissue studies beyond 6-week window in relevant animal models.

Community

Peak lean mass accrual and recovery benefits. Fat reduction may accompany lean gains. Response may plateau vs. weeks 3-4. Most experienced users cap cycle here.

Off-cycle (weeks 1-6 post)
Science

IGF-1R density recovers after agonist removal. Lean mass gains are generally maintained if nutrition is adequate. IGF-1 levels return toward baseline.

Community

Muscle fullness diminishes slightly as water retention resolves. Strength and lean mass largely retained. Sensitivity restored after 4-6 weeks off.

Pharmacokinetics

Half-Life
25h
Bioavailability
SC: not formally established; enhanced free fraction due to minimal IGFBP binding
Tmax
1-2 hours (estimated)
Data Confidence
low

Source: Estimated 20-30h based on reduced IGFBP affinity vs native IGF-1 (t½ ~12-15h); Conlon et al. 1995 PMID 7561636, Ballard et al. 1996 PMID 8708565

Pharmacokinetics: Active Dose Over Time

t½ = ~20-30 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
83
Molecular Weight
9,111 Da
Sequence
MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 946870-92-4

Who Should Consider IGF-1 LR3

  • Adults seeking lean mass and muscle hypertrophy support
  • Experienced peptide users with prior GH or IGF-1 exposure
  • Individuals recovering from muscle-wasting conditions (under medical supervision)
  • Researchers studying IGF-1R-mediated growth pathways

Related Peptides

What Changed for IGF-1 LR3

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]Long R3 IGF-I infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGFBP concentrations in the guinea pig (J Endocrinol, 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection (J Endocrinol, 1996) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]IGF-I, IGFBP-3, and cancer risk: systematic review and meta-regression analysis (Lancet, 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency (Acta Paediatr Suppl 1993) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C for long-term (up to 2 years). Short-term storage at 2-8°C acceptable for up to 3 months.
After Reconstitution
Refrigerate at 2-8°C, use within 30 days. Add 0.1% BSA or acetic acid to prevent adsorption to vial walls.
Temperature
-20°C long-term; 2-8°C short-term

Frequently Asked Questions

Regular IGF-1 is ~98% bound to binding proteins in circulation, leaving only a tiny free fraction active for 12-15 minutes. LR3 has extra amino acids plus a substitution that drops binding protein affinity by over 100-fold, so it circulates mostly free with a 20-30 hour functional half-life. DES eliminates all binding protein attachment for ~10x potency but clears in ~25 minutes. LR3 sits between them; longer-acting than both, moderate potency.

IGF-1 receptors exist on muscle and on virtually every other tissue. Sustained stimulation from a long-acting compound like LR3 drives growth in the colon, kidneys, adrenals, and spleen alongside skeletal muscle. In animal studies, significant organ enlargement occurred at 120 mcg/day continuous infusion. At recommended human doses (20-50 mcg/day for 4-6 weeks), the risk is low. At 80 mcg/day or stacked with other growth compounds, it climbs.

With a 20-30 hour half-life, timing is less critical than with DES. Systemic receptor occupancy stays elevated all day regardless of when you pin. Post-workout is commonly preferred because the muscle is primed for anabolic signaling and you'll be eating soon to manage any glucose lowering. Morning fasted works too, just eat promptly after.

This is flagged as an interaction for good reason. Both activate IGF-1R, LR3 provides continuous systemic stimulation over 20-30 hours while DES provides a sharp local pulse. Stacking them creates additive receptor load, amplifies organ growth risk, and significantly extends hypoglycemia risk. Most experienced users treat these as alternatives, not a stack.

Strongly advisable. Get baseline serum IGF-1, fasting glucose, and HbA1c. If your natural IGF-1 is already at the high-normal or above-normal range; possible with natural GH variation, obesity, or exogenous GH use; adding LR3 on top meaningfully increases proliferation risk. Elevated baseline IGF-1 is a contraindication.